Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by widespread immune dysregulation and multi-organ involvement. Unlike organ-specific autoimmune conditions, SLE affects multiple tissues simultaneously due to systemic immune activation. The disease is driven by loss of immune tolerance and production of autoantibodies against self-antigens. These immune responses lead to inflammation, tissue injury, and progressive organ dysfunction.SLE can have a fluctuating course and diverse clinical manifestations, affecting multiple organ systems with periods of remission and exacerbation.
What You Need to Know
Systemic lupus erythematosus develops when immune tolerance to self-antigens, particularly nuclear and cytoplasmic components, breaks down. Autoreactive B cells produce autoantibodies against DNA, RNA, and associated proteins, allowing immune responses to be directed toward structures that are present in nearly all cells. These autoantibodies circulate widely and bind to their targets, forming immune complexes that are not effectively cleared from the circulation.
Several core processes drive tissue injury in SLE:
widespread formation of circulating immune complexes rather than localised antibody activity
deposition of these complexes in tissues with high blood flow or filtration pressure
complement activation and inflammatory cell recruitment at deposition sites
Immune complexes activate complement and attract inflammatory cells, leading to vascular injury and tissue inflammation wherever they deposit. Because this process is systemic, damage is not confined to a single organ. The skin, kidneys, joints, blood vessels, and central nervous system are commonly affected, with clinical manifestations determined by the pattern and burden of immune complex accumulation rather than by antibody production alone. Vascular involvement is central, as inflammation often begins within small blood vessels before extending into surrounding tissue.
Disease activity in SLE fluctuates over time. Periods of heightened immune activation alternate with phases of relative quiescence, but immune processes rarely switch off completely. Each flare adds incremental injury through repeated immune complex deposition and inflammation. Even when symptoms improve, underlying tissue damage may persist or progress. Over time, this cumulative inflammatory burden leads to irreversible structural and functional organ damage, explaining why long-term outcomes are shaped by disease control across years rather than by individual flares in isolation.
Beyond the Basics
Loss of immune tolerance and autoantibody production
In systemic lupus erythematosus, immune tolerance fails at multiple levels. Central tolerance mechanisms do not adequately eliminate autoreactive lymphocytes during immune development, and peripheral regulatory systems fail to suppress those that escape into circulation. As a result, autoreactive B cells persist and undergo activation rather than remaining quiescent. Abnormal T-cell signalling compounds this process by providing inappropriate activation and survival cues, allowing autoreactive B cells to mature and produce high-affinity autoantibodies.
Because the targeted antigens are nuclear and cytoplasmic components present in nearly all cells, immune activation is continuously reinforced. The immune system is not responding to a transient trigger but to self-antigens that are always available. This constant antigen exposure explains why immune activation in SLE is sustained and why disease activity can re-emerge even after periods of apparent clinical stability.
Immune complex formation and impaired clearance
Autoantibodies in SLE bind to circulating self-antigens released during normal cell turnover, forming immune complexes. Under physiological conditions, these complexes are efficiently cleared by the reticuloendothelial system, particularly in the liver and spleen. In SLE, defects in clearance mechanisms allow immune complexes to persist in circulation for prolonged periods rather than being removed. Persisting immune complexes are carried throughout the circulation and deposit in tissues exposed to high blood flow, filtration pressure, or specialised vascular structures. Deposition is therefore determined by haemodynamic and structural factors rather than local antigen production. This explains why organ involvement can be widespread and unpredictable, affecting tissues far removed from the initial site of immune activation.
Complement activation and inflammatory amplification
Once immune complexes deposit in tissue, they activate the complement cascade. Complement proteins increase vascular permeability, recruit inflammatory cells, and amplify local immune responses. Neutrophils and monocytes accumulate at deposition sites and release proteolytic enzymes and reactive oxygen species, causing direct tissue injury and vascular damage. Ongoing complement activation leads to consumption of complement components, contributing to systemic immune imbalance. Rather than resolving inflammation, this process sustains immune dysregulation and promotes further immune complex formation. Complement activity therefore functions both as a mediator of tissue injury and as a driver of ongoing immune instability.
Organ-specific manifestations of a systemic process
The clinical manifestations of SLE depend on where immune complexes accumulate and how local tissue responds to inflammation. In the kidneys, immune complex deposition within the glomeruli disrupts filtration, leading to inflammation, protein leakage, and progressive loss of renal function. Cutaneous involvement arises from immune activity within skin vasculature, producing rashes that reflect vascular inflammation rather than primary epidermal disease. Joint manifestations result from synovial inflammation driven by immune complexes rather than direct cartilage destruction. Neurological features arise through vascular inflammation, blood–brain barrier disruption, and immune-mediated injury within the central nervous system. Although these features appear distinct, they all arise from the same underlying mechanism of systemic immune complex–driven inflammation.
Chronic inflammation and cumulative organ damage
Repeated cycles of immune activation sustain chronic inflammation across affected tissues. Cellular injury releases additional nuclear material into circulation, increasing the pool of available autoantigens and reinforcing immune complex formation. Over time, attempts at repair are overwhelmed by ongoing inflammatory injury.Fibrosis and scarring gradually replace functional tissue, reducing organ reserve even when inflammatory activity fluctuates. This cumulative damage explains why long-term outcomes in SLE are shaped by disease control over years rather than by individual flares. Preventing repeated immune-mediated injury is therefore central to preserving organ function and limiting irreversible damage.
Clinical Connections
Systemic lupus erythematosus commonly presents with non-specific features such as fatigue, joint pain, low-grade fever, and fluctuating functional capacity. These symptoms reflect systemic immune activity rather than isolated organ disease and may precede clear diagnostic findings by months or years. Because immune complex deposition varies in location and intensity over time, clinical manifestations can shift between systems or involve several organs simultaneously, making early disease patterns difficult to recognise and delaying diagnosis.
Several clinical features arise directly from immune complex–driven pathology:
episodic joint pain and swelling caused by synovial inflammation without cartilage destruction
fluctuating renal, neurological, or cutaneous features reflecting changing sites of immune complex deposition
systemic symptoms such as fatigue and fever driven by circulating inflammatory mediators rather than infection
Assessment focuses on pattern recognition over time rather than single abnormalities. Changes in renal function, blood counts, neurological status, or inflammatory markers may signal evolving immune activity even when symptoms appear mild. Disease progression is shaped by cumulative immune-mediated injury, not flare intensity alone. Early identification of changing trends and prompt escalation during flares reduce the risk of irreversible organ damage and preserve long-term functional reserve.
Concept Check
What immune mechanism underlies tissue injury in SLE?
Why is SLE considered a systemic rather than organ-specific autoimmune disease?
How do immune complexes cause inflammation and organ damage?
Why does SLE follow a relapsing–remitting course?
Why is early control of immune activity important in SLE?